Literature DB >> 24061520

PEComa of the gastrointestinal tract: clinicopathologic study of 35 cases with evaluation of prognostic parameters.

Leona A Doyle1, Jason L Hornick, Christopher D M Fletcher.   

Abstract

Perivascular epithelioid cell tumors (PEComas) are distinctive mesenchymal neoplasms that most often arise in the retroperitoneum, visceral organs, and abdominopelvic sites and usually show reactivity for melanocytic and smooth muscle markers. Fewer than 20 PEComas of the gastrointestinal (GI) tract have been reported, and behavior and criteria for malignancy are incompletely defined. The purpose of this study was to examine the clinicopathologic features of a series of GI PEComas and to evaluate prognostic parameters. A total of 35 PEComas of the GI tract were retrieved from consult and surgical files. Clinical and pathologic features were evaluated, and immunohistochemical analysis was performed. Clinical follow-up information was obtained from medical records and referring physicians. Nineteen patients were female and 16 male (median age 45 y; range, 7 to 70 y). One patient had tuberous sclerosis. Nineteen tumors arose in the colon, 12 in the small bowel, 2 in the stomach, and 1 each in gallbladder and omentum. Median tumor size was 6.2 cm (range, 0.8 to 22 cm). Three tumors were limited to the mucosa and submucosa, 8 extended to the muscularis propria, 15 to the subserosa/serosa, and 8 into the mesentery. The tumors were composed of nests and sheets of usually epithelioid cells with abundant granular eosinophilic to clear cytoplasm, surrounded by a delicate capillary vasculature. Thirteen tumors had mixed epithelioid and spindle cell components, and 2 were purely spindled. Sixteen tumors showed marked nuclear atypia. Seventeen tumors contained occasional pleomorphic cells, and 12 showed diffuse cellular pleomorphism. The median mitotic rate was 2/10 HPF (range, 0 to 36). Vascular invasion was present in 5 cases, and 16 tumors showed necrosis. By immunohistochemistry, 23/35 were positive for HMB45, 23/34 for melan-A, 15/25 for MiTF, 20/35 for smooth muscle actin, 26/35 for desmin, and 3/20 for TFE3. Focal cytoplasmic S100 protein was present in 5/27 cases, 2/25 cases were positive for KIT, and 1 case each was positive for EMA and keratin. Follow-up information was available for 31 patients (median 36 mo; range, 2 to 176 mo). Thirteen patients have developed metastases (10 liver, 3 peritoneum, 4 lymph node, 3 lung, 1 bone, 1 brain, and 1 adrenal). Thus far, 5 patients have died of disease. Metastases were significantly associated with marked atypia, diffuse pleomorphism, and mitoses ≥2/10 HPF. In summary, PEComas of the GI tract occur at similar frequency in female and male patients, most commonly involve the colon, and exhibit variable clinical behavior, ranging from benign lesions to aggressive, high-grade sarcomas. The presence of marked nuclear atypia, diffuse pleomorphism, and mitotic activity are the strongest predictors of malignant behavior.

Entities:  

Mesh:

Year:  2013        PMID: 24061520     DOI: 10.1097/PAS.0b013e31829caab3

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

Review 1.  Tuberous Sclerosis Complex with Multiple Gastrointestinal Manifestations. Case Report and Literature Review.

Authors:  Tariq A Hammad; Yaseen Alastal; Muhammad Ali Khan; Soukayna Rkaine; Thomas C Sodeman; Ali Nawras
Journal:  J Gastrointest Cancer       Date:  2016-12

Review 2.  Pancreatic PEComa is a novel member of the family of tuberous sclerosis complex-associated tumors: case report and review of the literature.

Authors:  Christopher P Hartley; David J Kwiatkowski; Lana Hamieh; Joel A Lefferts; Kerrington D Smith; Mikhail Lisovsky
Journal:  Virchows Arch       Date:  2016-10-18       Impact factor: 4.064

3.  Patterns of LC3A Autophagy Protein Expression in Keratoacanthomas.

Authors:  Efthimios Sivridis; Ioannis M Koukourakis; Stella Arelaki; Kostantina Balaska; Antonios Karpouzis; Alexandra Giatromanolaki
Journal:  Head Neck Pathol       Date:  2019-04-11

4.  Malignant perivascular epithelioid cell tumor (PEComa) of cervix with TFE3 gene rearrangement: a case report.

Authors:  Feifei Liu; Renya Zhang; Zi-Yu Wang; Qiuyuan Xia; Qin Shen; Shanshan Shi; Pin Tu; Qunli Shi; Xiaojun Zhou; Qiu Rao
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

5.  Long-lasting stable disease with mTOR inhibitor treatment in a patient with a perivascular epithelioid cell tumor: A case report and literature review.

Authors:  Ezequiel Flechter; Yaniv Zohar; Ludmila Guralnik; Maria Passhak; Gil Bar Sela
Journal:  Oncol Lett       Date:  2016-10-06       Impact factor: 2.967

6.  Incidental Nodal Lymphangioleiomyomatosis Is Not a Harbinger of Pulmonary Lymphangioleiomyomatosis: A Study of 19 Cases With Evaluation of Diagnostic Immunohistochemistry.

Authors:  J Kenneth Schoolmeester; Kay J Park
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

7.  Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications.

Authors:  Narasimhan P Agaram; Yun-Shao Sung; Lei Zhang; Chun-Liang Chen; Hsiao-Wei Chen; Samuel Singer; Mark A Dickson; Michael F Berger; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2015-06       Impact factor: 6.394

8.  Endometrial polyp-like perivascular epithelioid cell neoplasm associated with TFE3 translocation: report of one case.

Authors:  Yanting Hu; Lixia Wang; Hongqi Shi; Bin Hu
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

Review 9.  Perivascular epithelioid cell tumor in the duodenum: challenge in differential diagnosis.

Authors:  Zehong Chen; Huijuan Shi; Jianjun Peng; Yujie Yuan; Jianhui Chen; Wu Song
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

10.  Malignant perivascular epithelioid cell tumor of the ileum on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography with pathological correlation.

Authors:  Jeeban Paul Das; Jad Bou-Ayache; Marc J Gollub; Christopher C Riedl; Gary A Ulaner
Journal:  World J Nucl Med       Date:  2020-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.